A Phase 2/3 interventional study of Saline and Testosterone Undecanoate in Healthy Aging, Age-Related Sarcopenia and Testosterone Deficiency, sponsored by Norwegian School of Sport Sciences. Completed at 1 site in Norway. Open to male participants aged 55 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Norwegian School of Sport Sciences · Phase 2/3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This project's primary aim of this double-blinded, randomised, placebo-controlled trial is to investigate whether short-term testosterone administration +/- resistance exercise training induces a muscle memory response that can lead to longer-lasting benefits in aged human skeletal muscle.
The investigators will provide older men with the anabolic hormone, testosterone or placebo, with or without resistance training, followed by a period of testosterone abstinence and detraining, followed by a subsequent repeated period of resistance training (retraining). This will help determine if earlier encounters with short-term testosterone administration can be "remembered" and if adaptation to later retraining can be enhanced as a consequence of encountering testosterone earlier.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
This study's enrollment of 45 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.
Browse Sarcopenia studies →Norwegian School of Sport Sciences is the lead sponsor of 46 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The placebo group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and placebo abstinence (week 22) 4. Retraining (week 32)
Drug: Saline
The testosterone group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and testosterone abstinence (week 22) 4. Retraining (week 32)
Drug: Testosterone Undecanoate
The resistance exercise training + placebo group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and placebo abstinence (week 22) 4. Retraining (week 32)
Drug: Saline + Resistance exercise training
The resistance exercise training + testosterone group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and testosterone abstinence (week 22) 4. Retraining (week 32)
Drug: Testosterone Undecanoate + Resistance exercise training
Two placebo injections one at baseline and one week 3.
Also known as: Placebo
Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
Also known as: Nebido, Grünenthal (Grünenthal Norway AS)
Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
Also known as: Placebo + Resistance exercise training
Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
Also known as: Nebido, Grünenthal (Grünenthal Norway AS) + Resistance exercise training
Fat-free mass
Change and differences in fat-free mass (g) measured by dual x-ray absorptiometry (DEXA).
Time frame: Baseline and weeks 10, 22, 32
Skeletal muscle size and cross-sectional area (CSA)
Change and differences in skeletal muscle size and CSA measured by ultrasound
Time frame: Baseline and week 5,10, 16, 22, 27, 32
Skeletal muscle fibre CSA
Change and differences in skeletal muscle fibre CSA measure determined by immunohistochemistry
Time frame: Baseline and weeks 10, 22, 32
DNA methylation in skeletal muscle and blood
Methylation measured in difference/fold change values relative to appropriate controls.
Time frame: Baseline and weeks 10, 22, 32
Gene expression in skeletal muscle and blood
Gene expression measured in difference/fold change values relative to appropriate controls.
Time frame: Baseline and weeks 10, 22, 32
Myonuclei
Change and differences in number of myonuclei determined by immunohistochemistry
Time frame: Baseline and weeks 10, 22, 32
Satellite cells
Change and differences in number of satellite cells determined by immunohistochemistry
Time frame: Baseline and weeks 10, 22, 32
Isometric muscle strength
Change and differences in peak muscle strength (N) using isokinetic dynamometry
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Dynamic muscle strength
Change and differences in 1-repetition maximum
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Muscle force-velocity profiling
Change and differences in force (N) and velocity (m/s) derived from a 10-repetition FV-test
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Skeletal muscle stiffness
Change and differences in skeletal muscle stiffness measured by shear wave ultrasonography
Time frame: Baseline and weeks 10, 22, 32
Skeletal muscle tissue characteristics
Change and differences in skeletal muscle tissue characteristics determined by immunohistochemistry of muscle biopsies
Time frame: Baseline and weeks 10, 22, 32
Bone mineral density
Change and differences in bone mineral density (g/cm2) measured by DEXA
Time frame: Baseline and weeks 10, 22, 32
Bone health
Change and differences in bone health determined by bone health biomarkers in blood
Time frame: Baseline and weeks 10, 22, 32
Blood volume, haemoglobin and lean body mass
To investigate the association between blood volume, haemoglobin mass and lean body mass measured by carbon monoxide (CO) rebreathing and DEXA.
Time frame: Baseline and weeks 10, 22, 32
Blood parameters
Change and differences in steroid hormones in blood (testosterone, androstenediol, estradiol, and other relevant steroid markers, reproductive hormones (LH, FSH), binding protein (SHBG), cholesterol (total cholesterol, LDL, HDL), and PSA level, and endocrine biomarkers (IGF-1 and P-III-NP).
Time frame: Baseline and weeks 10, 22, 32
Aging males symptoms
Change and differences in Aging male symptoms score (1="none", 5="extremely severe")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Well-being
Change and differences in WHO5 well-being index score (0="at not time", 5="all of the time")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Psychological distress
Change and differences in SCL-10 symptoms score (1="not at all", 4="extremely")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Fatigue
Change and differences in shortened fatigue questionnaire score (1="yes, that is true", 7="no, that is not true")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Sleep
Change and differences in Jenkins sleep scale score (0="not at all", 5="22-31days")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Sexual function
Change and differences in sexual function score (items from Health-related quality of life (HRQOL) questionnaire), (
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Body perception
Change and differences in Body Perception Questionnaire very short form score (1=never, 5=always)
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Anger
Change and differences in The State Anger subscale of STAXI-2score (0="not at all", 3="very much")
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Mania
Change and differences in Altman Self-Rating Mania Scale (ASRM) score
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Suicide thoughts
Change and differences in Suicide thoughts from Montgomery and Åsberg Depression Rating Scale
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Cognitive function
Change and differences in cognitive function measured by emotion recognition tasks and cognitive reflection tasks
Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32
Exercise motivation
Change and differences in perceived motivation score and motivation type
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Exercise effort
Change and differences in rating of perceived exertion for effort (Borg CR-10 RPE)
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Exercise discomfort
Change and differences in rating of perceived exertion for discomfort (sRPD) score
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Session pleasure and displeasure
Change and differences in perceived pleasure/displeasure with the training session using the pleasure/displeasure feeling scale (sPDF), (-5=very bad", 5="very good")
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Exercise enjoyment
Change and differences in exercise enjoyment scale score (1="not at all", 7=extraordinary")
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Reps in reserve
Change and differences in the ability to predict reps in reserve
Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Plan to share: No — No identifiable information will be included in any publication. Genome-Wide DNA Methylation and Gene Expression will be deposited with full open access on Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) an internationally recognised database. GEO data derived from human samples will be anonymous, with no identifiable information. GEO data will be deposited at the same time as a publication. All non-identifiable results from the project will be ultimately published in peer-reviewed journals. In addition, all image files, raw excel/ .csv / txt /word files for any of the other analyses described above in the methods will be available as either supplementary files on the publisher's website or fully accessible on request to the corresponding author/authors.
Ran from Sep 2024 to primary completion in Dec 2025, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Testosterone undecanoate
Norwegian School of Sport Sciences